Akash Agarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Akash Agarwal has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Maitreyee Panda
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, India
15 shared publicationsAnanya Pramanik
Department of Dermatology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India
4 shared publications- Maitreyee Panda
Department of Dermatology, Venereology, and Leprosy, Institute of Medical Sciences and SUM Hospital, K-8 Kalinga Nagar, Bhubaneshwar, Odisha, India
4 shared publications - Anupam Das
Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India
3 shared publications Farheen Begum
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Odisha, India
3 shared publications- Parul Bansal
Department of Dermatology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India
3 shared publications
Latest Publications
- 7 February 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5)
Therapeutic Efficacy of Oral Tofacitinib in Pediatric Prurigo Nodularis: A Case Series With a Review of Literature
- 7 February 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5)
Therapeutic Efficacy of Oral Tofacitinib in Pediatric Prurigo Nodularis: A Case Series With a Review of Literature
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 17 (4) , 564-566
Red Scrotum Syndrome Responding to Doxycycline: A Report of Two Cases with a Review of the Literature
- 20 January 2026
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 17 (4) , 564-566
Open AccessRed Scrotum Syndrome Responding to Doxycycline: A Report of Two Cases with a Review of the Literature
- Open Access
- 16 October 2025
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 92, 741-743
Gliptin-induced dyshidrosiform bullous pemphigoid: A rare occurrence
Gliptin-induced dyshidrosiform bullous pemphigoid: A rare occurrence
- 16 October 2025
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 92, 741-743
Open AccessGliptin-induced dyshidrosiform bullous pemphigoid: A rare occurrence
Gliptin-induced dyshidrosiform bullous pemphigoid: A rare occurrence
- Open Access
- 14 August 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (5) , 835-839
Genitogluteal Porokeratoses: A Case Series of a Rare Entity
- 14 August 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (5) , 835-839
Open AccessGenitogluteal Porokeratoses: A Case Series of a Rare Entity
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Indian Journal of Paediatric Dermatology
- Vol. 26 (2) , 79-89
Cutaneous Manifestations of Pediatric Hematological Malignancies: A Narrative Review
Malignancies in the pediatric population can cause significant morbidity and mortality in the affected individual. Hematological malignancies are the most common type of cancer in children. Moreover, its incidence has drastically increased due to genetic alterations or environmental exposure to several carcinogens. Cutaneous manifestations, although rare, may be the sole presentation and may precede, follow or occur simultaneously with the primary disease. Hence, it is important to be aware about the varied morphology, distribution, and evolution of the lesions for prompt diagnosis and treatment. However, there is a paucity of the literature in the pediatric population. The objective of the review is to enumerate the different cutaneous symptoms and signs of hematological malignancies due to the primary disease, chemotherapy, and stem-cell transplantation in children.
- 1 April 2025
- Published by Wolters Kluwer Health in Indian Journal of Paediatric Dermatology
- Vol. 26 (2) , 79-89
Open AccessCutaneous Manifestations of Pediatric Hematological Malignancies: A Narrative Review
Malignancies in the pediatric population can cause significant morbidity and mortality in the affected individual. Hematological malignancies are the most common type of cancer in children. Moreover, its incidence has drastically increased due to genetic alterations or environmental exposure to several carcinogens. Cutaneous manifestations, although rare, may be the sole presentation and may precede, follow or occur simultaneously with the primary disease. Hence, it is important to be aware about the varied morphology, distribution, and evolution of the lesions for prompt diagnosis and treatment. However, there is a paucity of the literature in the pediatric population. The objective of the review is to enumerate the different cutaneous symptoms and signs of hematological malignancies due to the primary disease, chemotherapy, and stem-cell transplantation in children.
- 7 January 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (7) , 1312-1314
Trachyonychia secondary to pediatric alopecia areata responding to oral tofacitinib therapy: a case report and review of literature
- 7 January 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (7) , 1312-1314
Trachyonychia secondary to pediatric alopecia areata responding to oral tofacitinib therapy: a case report and review of literature
- 2 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (5) , 1009-1013
Modified intralesional aciclovir treatment in the management of recalcitrant palmoplantar and ungual warts: a case series of 14 patients
In this retrospective study, we evaluated the efficacy and safety of modified intralesional aciclovir for the treatment of recalcitrant palmoplantar and ungual warts in 14 patients (7 men and 7 women) of mean age 24.5 years (SD 8.19). Modified aciclovir (50 mg mL–1) was prepared by mixing 250 mg of lyophilized aciclovir powder with 4 mL of distilled water and 1 mL of 2% lignocaine. Then, this solution was injected into each wart at a dose of 0.1 mL or until blanching occurred. Every 2 weeks, the eschar was pared off and the treatment was repeated until a complete cure was observed, for a maximum of five sessions. After five sessions, 82% (n = 55/67) of warts showed a complete response, and 18% (n = 12/67) showed a partial response. Adverse effects reported included lesional tenderness for 2–3 days following injection in 23% (n = 3/13) of patients. Blistering and nail-plate damage were each seen in one patient. Modifying aciclovir treatment by adding lignocaine resulted in an unaltered concentration of aciclovir while maintaining its efficacy. The efficacy and safety were comparable with those reported for previous studies but with greater patient acceptability.
- 2 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (5) , 1009-1013
Modified intralesional aciclovir treatment in the management of recalcitrant palmoplantar and ungual warts: a case series of 14 patients
In this retrospective study, we evaluated the efficacy and safety of modified intralesional aciclovir for the treatment of recalcitrant palmoplantar and ungual warts in 14 patients (7 men and 7 women) of mean age 24.5 years (SD 8.19). Modified aciclovir (50 mg mL–1) was prepared by mixing 250 mg of lyophilized aciclovir powder with 4 mL of distilled water and 1 mL of 2% lignocaine. Then, this solution was injected into each wart at a dose of 0.1 mL or until blanching occurred. Every 2 weeks, the eschar was pared off and the treatment was repeated until a complete cure was observed, for a maximum of five sessions. After five sessions, 82% (n = 55/67) of warts showed a complete response, and 18% (n = 12/67) showed a partial response. Adverse effects reported included lesional tenderness for 2–3 days following injection in 23% (n = 3/13) of patients. Blistering and nail-plate damage were each seen in one patient. Modifying aciclovir treatment by adding lignocaine resulted in an unaltered concentration of aciclovir while maintaining its efficacy. The efficacy and safety were comparable with those reported for previous studies but with greater patient acceptability.
- Open Access
- 26 October 2024
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 4, 131
Pustular exacerbation of psoriasis precipitated by erythema multiforme like pityriasis rosea
- 26 October 2024
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 4, 131
Open AccessPustular exacerbation of psoriasis precipitated by erythema multiforme like pityriasis rosea
- Open Access
- 11 October 2024
- Published by Scientific Scholar in Indian Journal of Postgraduate Dermatology
- Vol. 3, 86-87
Trichoteiromania Presenting as a Patch of Localised Hair Loss: A Diagnostic Challenge
- 11 October 2024
- Published by Scientific Scholar in Indian Journal of Postgraduate Dermatology
- Vol. 3, 86-87
Open AccessTrichoteiromania Presenting as a Patch of Localised Hair Loss: A Diagnostic Challenge
- Open Access
- 11 October 2024
- Published by Scientific Scholar in Indian Journal of Postgraduate Dermatology
- Vol. 3, 71-72
Squamous Cell Carcinoma Arising from Trophic Ulcer in a Treated Case of Hansen’s Disease
- 11 October 2024
- Published by Scientific Scholar in Indian Journal of Postgraduate Dermatology
- Vol. 3, 71-72
Open AccessSquamous Cell Carcinoma Arising from Trophic Ulcer in a Treated Case of Hansen’s Disease